69|466|Public
25|$|Leukemias* are {{progressive}} {{proliferation of}} cancerous {{white blood cells}} within the bone marrow, resulting in destruction of the bone marrow and pancytopenia in many cases. Types of leukemia in dogs include acute lymphoblastic leukemia, acute myelocytic leukemia, acute monocytic leukemia, <b>acute</b> <b>myelomonocytic</b> <b>leukemia,</b> acute megakaryocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic basophilic leukemia, and chronic eosinophilic leukemia (or hypereosinophilic syndrome).|$|E
5000|$|... #Caption: Diffusely swollen gums due to {{infiltration}} by leukemic {{cells in}} a person with <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> ...|$|E
50|$|<b>Acute</b> <b>myelomonocytic</b> <b>leukemia</b> (AMMoL) {{is a form}} {{of acute}} myeloid leukemia that {{involves}} a proliferation of CFU-GM myeloblasts and monoblasts.|$|E
40|$|In a {{group of}} 650 {{patients}} with hyperthyroidism treated with radioiodine between 1945 and 1961, two cases of leukemia occurred. In one patient the diagnosis of chronic lymphatic leukemia was made {{three years after the}} I 131 therapy. <b>Acute</b> or subacute <b>myelomonocytic</b> <b>leukemia</b> developed in the other patient after an interval of 14 years. However, no conclusions can be drawn regarding a possible causal relationship between such therapy and the subsequent occurrence of leukemia. With passage of time, an ever increasing number of cases of leukemia can be expected in such patients on the basis of natural occurrence alone...|$|R
40|$|Background <b>Myelomonocytic</b> <b>acute</b> myeloid <b>leukemia</b> (M 4 -AML) is {{frequently}} {{associated with the}} cytogenetic marker inv(16) and/or the presence of eosinophilia. The {{aim of this study}} was to analyze the incidence and prognostic role of these factors in a large series of patients. Design and Methods Adult patients with acute myeloid leukemia consecutively enrolled in the GIMEMA trials AML 10 and LAM 99 p were retrospectively analyzed. Results Among 1686 patients, 400 cases of M 4 -AML were identified; of these, 78...|$|R
40|$|Interleukin 1 (IL- 1) or lymphocyte-activating factor, a {{monokine}} {{released in}} vitro by cultured monocytes or macrophages, acts {{on a variety}} of somatic and immunerelated target cells in a genetically unrestricted manner (1 - 5). It has long been recognized that fibroblasts appear at sites of inflammatory reactions after macrophages and play a pivotal role in the repair of damaged connective tissue by synthesizing and remodeling components of the matrix (e. g., collagens, fibronectin, and proteoglycans) (6). In this report, we have observed that IL- 1 is a potent stimulator of fibroblast collagenase production in vitro. This finding suggests that ILl may be a major effector molecule by which macrophages modulate not only fibroblast growth but collagenase production as well (4, 5). Materials and Methods IL- 1 Purification. In preliminary studies, we found that IL- 1 isolated from normal human peripheral blood monocytes was contaminated by lymphokines (personal observation by A. E. Postlethwaite and L. Lachman). However, IL-I from monoblasts from patients with <b>acute</b> monocytic or <b>myelomonocytic</b> <b>leukemia</b> was free of contaminating lyrnphokines and its physicochemica...|$|R
50|$|He {{was briefly}} married to actress Karey Louis. His second {{marriage}} was to Theresa Fargo, {{the mother of}} his daughter Ashley, until her death from <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> on November 5, 1992, not long after Ashley's birth. She had developed the disease during her pregnancy.|$|E
50|$|Cooke {{played a}} {{prominent}} role in arranging Pope Paul's visit to New York in October, and became Vicar General of the Archdiocese two days after his consecration, on December 15, 1965. He was diagnosed with <b>acute</b> <b>myelomonocytic</b> <b>leukemia,</b> a form of cancer, that year as well.|$|E
50|$|In December, 2016, Kagawa was {{admitted}} to hospital for treatment of <b>acute</b> <b>myelomonocytic</b> <b>leukemia.</b> He was transferred {{to a hospital in}} Tokyo for further treatment in January 2017, but his condition would deteriorate suddenly in the evening of April 4. Ryo Kagawa died peacefully in hospital on the morning of April 5, 2017.|$|E
40|$|Objective: Unusual {{clinical}} course Background: Renal {{failure is}} a common presentation of <b>acute</b> <b>myelomonocytic</b> and monocytic <b>leukemia.</b> It is usually the re-sult of a combined glomerular and tubular dysfunction and {{is associated with a}} poor prognosis. No guidelines exist for treatment. Case Report: We herein describe the case of a 78 -year-old Caucasian man who presented with acute myeloid leukemia M 5, leukostasis with a white count of 340 000 /ml, and acute renal failure with a creatinine of 7. 7 /dL. The patient was initially treated with leukapheresis and 3 days of idarubicin in the setting of continuous renal replacement therapy that resulted in rapid reversal of his renal failure. He then received 7 days of continuous infusion cy-tarabine and went into a complete remission. Conclusions: Renal failure may complicate the presentation of AML but can be reversible with treatment. Dose adjustment of the chemotherapy is not needed and the treatment can be greatly facilitated with the use of continuous renal replacement therapy, as indicated in our case report. In addition, we emphasize that organ dysfunction, even in elderly patients, is not necessarily a contraindication to aggressive treatment if it is felt to be disease...|$|R
40|$|Acute {{myeloid leukemia}} arising from chronic <b>myelomonocytic</b> <b>leukemia</b> is {{currently}} classified as {{acute myeloid leukemia}} with myelodysplasia-related changes, a high-risk subtype. However, the specific features of these cases have not been well described. We studied 38 patients with chronic <b>myelomonocytic</b> <b>leukemia</b> who progressed to acute myeloid leukemia. We compared the clinicopathologic and genetic features of these cases with 180 patients with de novo acute myeloid leukemia and 34 patients with acute myeloid leukemia following myelodysplastic syndromes. We also examined features associated with progression from chronic <b>myelomonocytic</b> <b>leukemia</b> to <b>acute</b> myeloid leukemia by comparing the progressed chronic <b>myelomonocytic</b> <b>leukemia</b> cases with a cohort of chronic <b>myelomonocytic</b> <b>leukemia</b> cases that did not transform to acute myeloid leukemia. Higher white blood cell count, marrow cellularity, karyotype risk score, and Revised International Prognostic Scoring System score were associated with more rapid progression from chronic <b>myelomonocytic</b> <b>leukemia</b> to <b>acute</b> myeloid leukemia. Patients with acute myeloid <b>leukemia</b> ex chronic <b>myelomonocytic</b> <b>leukemia</b> were older (P< 0. 01) {{and less likely to}} receive aggressive treatment (P= 0. 02) than de novo acute myeloid leukemia patients. Most cases showed monocytic differentiation and fell into the intermediate acute myeloid leukemia karyotype risk group; 55 % had normal karyotype and 17 % had NPM 1 mutation. Median overall survival was 6 months, which was inferior to de novo acute myeloid leukemia (17 months, P= 0. 002) but similar to post myelodysplastic syndrome acute myeloid leukemia. On multivariate analysis of all acute myeloid leukemia patients, only age and karyotype were independent prognostic variables for overall survival. Our findings indicate that acute myeloid <b>leukemia</b> following chronic <b>myelomonocytic</b> <b>leukemia</b> displays aggressive behavior and support placement of these cases within the category of acute myeloid leukemia with myelodysplasia-related changes. The poor prognosis of these patients may be related to an older population and lack of favorable-prognosis karyotypes that characterize many de novo acute myeloid leukemia cases...|$|R
25|$|P-Orridge was {{diagnosed}} with chronic <b>myelomonocytic</b> <b>leukemia</b> in October 2017.|$|R
5000|$|King {{became an}} {{associate}} editor of the Journal of Molecular Evolution in 1971, shortly after the journal's founding. He co-authored a 1981 textbook, Biology, The Science of Life. King died unexpectedly in 1983 from a brain hemorrhage caused by <b>acute</b> <b>myelomonocytic</b> <b>leukemia.</b> [...] King was survived by his second wife Ethel and their two children as well as six children from his first marriage.|$|E
50|$|Acute {{myeloblastic leukemia}} (AML) {{is a group}} of {{malignant}} bone marrow neoplasms of myeloidprecursors of white blood cells. <b>Acute</b> <b>myelomonocytic</b> <b>leukemia</b> (AML-M4) is a common type of pediatric AML. However, the condition is rare and represents approximately 3% of all leukemias during childhood and has an incidence of 1.1 - 1.7 per million per year. The symptoms may be aspecific: asthenia, pallor, fever, dizziness and respiratory symptoms. More specific symptoms are bruises and/or (excessive) bleeding, coagulation disorders (DIC), neurological disorders and gingival hyperplasia. Diagnostic methods include blood analysis, bone marrow aspirate for cytochemical, immunological and cytogeneticalanalysis, and cerebrospinal fluid (CSF) investigations. A characteristic chromosomal abnormalityobserved in AML-M4 is inv(16). Treatment includes intensive multidrug chemotherapy and in selected cases allogeneic bone marrow transplantation. Nevertheless, outcome of AML remains poor with anoverall survival of 35-60%. Children with AML-M4 carrying the inv(16) abnormality have a better prognosis (61% 5-year overall survival). New therapeutics are required to increase the probability of cure in this serious disorder.|$|E
40|$|Myelodysplastic {{syndrome}} is a closely related group of acquired bone marrow disorders characterized by ineffective and dysplastic hematopoiesis. These clonal disorders frequently progress to acute leukemia. <b>Acute</b> <b>myelomonocytic</b> <b>leukemia</b> with eosinophilia {{is characterized by}} an increase in abnormal eosinophils in the bone marrow, relatively good clinical course and inv (16) chromosomal abnormality. We experienced one case of refractory anemia with excess blasts which progressed to refractory anemia with excess blasts in transformation and finally to <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> with eosinophilia showing peculiar chromosomal abnormalities of der (1; 7) ...|$|E
40|$|Background. Chronic <b>myelomonocytic</b> <b>leukemia</b> {{is close}} to, but {{separate}} from both myeloproliferative neoplasms and myelodysplastic syndromes, and shows either myeloproliferative or myelodysplastic features. We ask whether this distinction {{may have a}} molecular basis. Design and Methods. We established the gene expression profiles of 39 samples of chronic <b>myelomonocytic</b> <b>leukemia</b> (including 12 CD 34 -positive) and 32 CD 34 -positive samples of myelodysplastic syndromes by using Affymetrix microarrays, and studied the status of 18 genes by Sanger sequencing and array-comparative genomic hybridization in 53 samples. Results. Analysis of 12 mRNAS from chronic <b>myelomonocytic</b> <b>leukemia</b> established a gene expression signature of 122 probe sets differentially expressed between proliferative and dysplastic cases of chronic <b>myelomonocytic</b> <b>leukemia.</b> As compared to the former, the latter overexpressed genes involved in red blood cell biology. When applied to 32 myelodysplastic syndromes this gene expression signature was able to discriminate refractory anemias with ring sideroblasts from refractory anemias with excess of blasts. By comparing mRNAS from these two forms of myelodysplastic syndromes we derived a second gene expression signature. This signature separated the myelodysplastic and myeloproliferative forms of chronic <b>myelomonocytic</b> <b>leukemias.</b> These results were validated by using two independent gene expression data sets. We found that myelodysplastic chronic <b>myelomonocytic</b> <b>leukemias</b> are characterized by mutations in transcription/epigenetic regulators (ASXL 1, RUNX 1, TET 2) and splicing genes (SRSF 2) {{and the absence of}} mutations in signaling genes. Conclusions. Myelodysplastic chronic <b>myelomonocytic</b> <b>leukemias</b> and refractory anemias with ring sideroblasts share a common expression program suggesting {{they are part of a}} continuum, which is not totally explained by their similar but not identical mutation spectrum...|$|R
25|$|Treatment for {{juvenile}} <b>myelomonocytic</b> <b>leukemia</b> {{can include}} splenectomy, chemotherapy, and bone marrow transplantation.|$|R
50|$|Similar to PDGFRB-ETV6 translocations, these translocations are {{generally}} in-frame and encode for fusion proteins with their PDGFRB-derived tyrosine kinase being continuously active and responsible for causing the potentially malignant growth of its myeloid and/or lymphoid harboring cells. Patients are usually middle-aged men. They commonly present with anemia, eosinophilia, monocytosis, and splenomegaly {{and have their}} disease classified as chronic <b>myelomonocytic</b> <b>leukemia,</b> atypical chronic <b>myelomonocytic</b> <b>leukemia,</b> juvenile <b>myelomonocytic</b> <b>leukemia,</b> myelodysplastic syndrome, <b>acute</b> myelogenous leukemia, acute lymphoblastic leukemia, or T lymphoblastic lymphoma. Diganosis relies on cytogenetic analyses to detect breakpoints in the long arm of chromosome 5 by Fluorescence in situ hybridization. These patients usually respond well to imatinib therapy.|$|R
40|$|Abstract. Acute {{myeloid leukemia}} {{presenting}} as leukemia cutis (LC) with hepatocellular carcinoma is extremely rare. The current study presents {{a case of}} a 53 -year-old male with generalized cutaneous nodules on the face and anterior chest wall. Laboratory tests, including bone marrow biopsy revealed <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> (AML-M 4) with skin and tonsilar involvement. Liver magnetic resonance imaging (MRI) revealed a 6 -cm mass in hepatic segments 4 and 8, and a liver biopsy demonstrated that hepatocellular carcinoma cells and immature blast cells coexisted. Although LC has been reported in Korea, a case of LC associated with <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> was diagnosed simultaneously with hepatocellular carcinoma and tonsillar involvement. The present study describes this case with a review of the literature...|$|E
40|$|A not yet {{recorded}} translocation, t(3 : 17) (q 21;q 23), {{detected in}} a case of <b>acute</b> <b>myelomonocytic</b> <b>leukemia,</b> is reported. In spite of an aggressive cytotoxic chemotherapy, the disease showed a rapid fatal course, confirming the dismal prognostic significance of structural, 'primary' chromosomal abnormalities in acute leukemias...|$|E
40|$|A 69 -year-old woman {{treated for}} 31 months with daily oral {{cyclophosphamide}} for refractory rheumatoid disease developed <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> 21 / 2 years after stopping the drug. The {{possibility of a}} casual association between the therapy and subsequent leukaemia {{is supported by the}} growing experience with cytotoxic agents...|$|E
40|$|Chronic <b>myelomonocytic</b> <b>leukemia</b> is a clonal {{stem cell}} {{disorder}} that is characterized mainly by absolute peripheral monocytosis. This disease can present myeloproliferative and myelodysplastic characteristics. According to the classification {{established by the}} World Health Organization, chronic <b>myelomonocytic</b> <b>leukemia</b> is inserted {{in a group of}} myeloproliferative/myelodysplastic disorders; its diagnosis requires the presence of persistent monocytosis and dysplasia involving one or more myeloid cell lineages. Furthermore, there should be an absence of the Philadelphia chromosome and the BCR/ABL fusion gene and less than 20 % blasts in the blood or bone marrow. Phenotypically, the cells in chronic <b>myelomonocytic</b> <b>leukemia</b> can present <b>myelomonocytic</b> antigens, such as CD 33 and CD 13, overexpressions of CD 56 and CD 2 and variable expressions of HLA-DR, CD 36, CD 14, CD 15, CD 68 and CD 64. The increase in the CD 34 expression may be associated with a transformation into acute leukemia. Cytogenetic alterations are frequent in chronic <b>myelomonocytic</b> <b>leukemia,</b> and molecular mutations such as NRAS have been identified. The present article reports on a case of chronic <b>myelomonocytic</b> <b>leukemia,</b> diagnosed by morphologic and phenotypical findings that, despite having been suggestive of acute monocytic leukemia, were differentiated through a detailed analysis of cell morphology. Furthermore, typical cells of chronic lymphocytic leukemia were found, making this a rare finding...|$|R
50|$|Meehl died on February 14, 2003 at {{his home}} in Minneapolis of chronic <b>myelomonocytic</b> <b>leukemia.</b>|$|R
5000|$|... 17. 2011 Expression of NOV and BNIP3 gene in mouse <b>myelomonocytic</b> <b>leukemia</b> and its {{significance}} ...|$|R
40|$|Aspergillus terreus is an {{uncommon}} cause of human disease. A patient with <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> is described who developed an invasive pulmonary infection with A terreus {{characterized by an}} air-crescent sign on chest roentgenogram. Previous reports of A terreus infections and the pathogenesis and significance of an air-crescent sign in invasive pulmonary aspergillosis are reviewed...|$|E
40|$|Thirteen {{previously}} untreated patients aged 70 {{and above}} with acute nonlymphocytic leukemia {{were treated with}} aclarubicin (ACR) alone. Among 10 cases (3, acute myelocytic leukemia; 4, acute myelomonocytic leukemia; 2, acute monocytic leukemia; and one, acute erythroleukemia) in which an evaluation was possible, 5 cases (3, acute myelomonocytic leukemia; and 2, acute monocytic leukemia) obtained complete remission (CR). The CR rate was 83 % in 6 patients with <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> or acute monocytic leukemia. The median CR duration and survival was 7. 5 and 10 + months, respectively. Although side effects of the drug on digestive system such as nausea, vomiting and anorexia were observed in all patients, they were controllable by conventional treatments. The results suggest that ACR is effective for the clinical management of elderly patients with acute nonlymphocytic leukemia, especially those with <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> or acute monocytic leukemia. </p...|$|E
40|$|Mucormycosis (zygomycosis) is an {{emerging}} fungal disease in allogeneic {{hematopoietic stem cell}} transplant (allo-HSCT) recipients. A 30 -year-old woman diagnosed with <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> and needing allo-HSCT presented pulmonary and cerebral infection due to Rhizomucor pusillus. This fungal infection was treated with surgical treatment and posaconazole delayed-release tablets. This strategy allowed reaching high drug levels {{that could not be}} obtained with the posaconazole solution...|$|E
50|$|Lenzilumab (INN) (alternative {{identifier}} KB003) is a humanized {{monoclonal antibody}} (class IgG1 kappa) that targets colony stimulating factor 2 (CSF2)/granulocyte-macrophage colony stimulating factor (GM-CSF) {{designed for the}} treatment of chronic <b>myelomonocytic</b> <b>leukemia</b> (CMML) and juvenile <b>myelomonocytic</b> <b>leukemia</b> (JMML). In vitro studies on human cells have demonstrated that Lenzilumab can induce sensitivity in myeloid and monocytic cells suggesting the antibody's applicability in CMML and JMML indications.|$|R
50|$|Patients {{with the}} cited PDGFRB fusion genes {{generally}} present {{with a combination}} of eosinophilia and monocytosis, increased bone marrow eosinophils, and/or eosinophil tissue infiltrations but otherwise a disease resembling chronic <b>myelomonocytic</b> <b>leukemia,</b> atypical chronic myelogenous <b>leukemia,</b> juvenile <b>myelomonocytic</b> <b>leukemia,</b> myelodysplastic syndrome, <b>acute</b> myelogenous leukemia, acute lymphoblastic leukemia, or T lymphoblastic lymphoma. These patients usually respond well to imatinib or other tyrosine kinase inhibitor therapy.|$|R
40|$|Chronic <b>myelomonocytic</b> <b>leukemia</b> is a {{very rare}} blood cancer {{observed}} mostly in the elderly. Here we report the incidence trends and survival of patients with chronic <b>myelomonocytic</b> <b>leukemia</b> over a 15 -year period (1993 - 2007). Cases were provided by the population-based Girona Cancer Registry. The crude incidence rate was 0. 72 / 100, 000 inhabitants/year. No statistically significant increase in trends was detected over the 15 years. Median overall survival was 28 months although survival markedly decreased with advancing age. The 5 -years observed and relative survival were 20 % and 29 %, respectively. This is the first population-based study that reports the incidence and survival of chronic <b>myelomonocytic</b> <b>leukemia</b> in Spai...|$|R
40|$|The cytogenetic, hematologic, and {{clinical}} {{characteristics of a}} 13 -year-old girl with acquired t(6; 9) (p 23;q 34) and dysmyelopoietic syndrome developing into <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> are described, bringing {{the total number of}} patients with t(6; 9) and hematologic disease described in the literature up to 19. The diagnosis has been acute myeloid leukemia in the great majority of these patients; only four have had <b>acute</b> <b>myelomonocytic</b> <b>leukemia.</b> High resolution analysis at the 550 band stage localized the breakpoints in chromosomes # 6 and # 9 to p 23 and 9 q 34. 3, respectively. Previous investigations employing high resolution cytogenetics have mapped the typical 9 q breakage site in chronic myeloid leukemia to 9 q 34. 1. In situ hybridization studies have demonstrated that the cellular oncogene c-abl remains on the derivative 9 q+ chromosome in t(6; 9), whereas it is moved to the Ph marker in t(9; 22). Thus, the combined data indicate that c-abl is located between 9 q 34. 1 and 9 q 34. 3, i. e., in subband 9 q 34. 2 or its immediate vicinity...|$|E
40|$|The {{association}} of {{acute myeloid leukemia}} (AML) with plasmacytosis is a known, although rare event. There are very few case reports documenting {{an increase in the}} number of plasma cells at the time of AML diagnosis. Here, we present the case of a 65 -year-old male diagnosed as <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> with exuberant plasmacytosis, which posed a difficulty in diagnosis. Paracrine interleukin- 6 production by leukemic blast cells is thought to contribute to this associated reactive plasma cell proliferation...|$|E
40|$|A {{series of}} {{monoclonal}} antibodies have been characterized that define four surface antigens (MY 3, MY 4, MY 7, and MY 8) of human myeloid cells. They {{were derived from}} a fusion of the NS- 1 plasmacytoma cell line with splenocytes from a mouse immunized with human <b>acute</b> <b>myelomonocytic</b> <b>leukemia</b> cells. MY 3 and MY 4 are expressed by normal monocytes and by greater than 90 % of patients with acute monocytic leukemia or <b>acute</b> <b>myelomonocytic</b> <b>leukemia,</b> but are detected much less often on other types of myeloid leukemia. MY 7 is expressed by granulocytes, monocytes, and 5 % of normal bone marrow cells. 79 % of all acute myeloblastic leukemia (AML) patients tested (72 patients) express MY 7 without preferential expression by any AML subtype. MY 8 is expressed by normal monocytes, granulocytes, all peroxidase-positive bone marrow cells, and 50 % of AML patients. MY 3, MY 4, and MY 8 define myeloid differentiation antigens {{in that they are}} not detected on myeloid precursor cells and appear at discrete stages of differentiation. These antigens are not expressed by lymphocytes, erythrocytes, platelets, or lymphoid malignancies. The monoclonal antisera defining these antigens have been used to study differentiation of normal myeloid cells and malignant cell lines...|$|E
5000|$|CHZ868 â€” a type II JAK2 {{inhibitor}} {{for use in}} {{myeloproliferative disorders}} and chronic <b>myelomonocytic</b> <b>leukemia</b> (CMML).|$|R
40|$|Juvenile <b>myelomonocytic</b> <b>leukemia</b> {{is a rare}} {{myeloproliferative}} disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile <b>myelomonocytic</b> <b>leukemia</b> increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenile <b>myelomonocytic</b> <b>leukemia</b> are currently lacking. Here we propose criteria to evaluate {{the response to the}} non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogenetic, molecular and chimerism response) which serve to describe the heterogeneous picture of response to therapy in each individual case. It is hoped that these criteria will facilitate the comparison of results between clinical trials in juvenile <b>myelomonocytic</b> <b>leukemia...</b>|$|R
40|$|Somatic {{mutations}} of the spliceosomal machinery occur {{frequently in}} adult patients with myelodysplastic syndrome (MDS). We resequenced SF 3 B 1, U 2 AF 35, and SRSF 2 in 371 children with MDS or juvenile <b>myelomonocytic</b> <b>leukemia.</b> We found missense mutations in 2 juvenile <b>myelomonocytic</b> <b>leukemia</b> cases and in 1 child with systemic mastocytosis with MDS. In 1 juvenile <b>myelomonocytic</b> <b>leukemia</b> patient, the SRSF 2 mutation that initially coexisted with an oncogenic NRAS mutation was absent at relapse, whereas the NRAS mutation persisted and a second, concomitant NRAS mutation later emerged. The patient with systemic mastocytosis and MDS carried both mutated U 2 AF 35 and KIT {{in a single}} clone as confirmed by clonal sequencing. In the adult MDS patients sequenced for control purposes, we detected previously reported mutations in 7 / 30 and a novel SRSF 2 deletion (c. 284 - 307 del) in 3 of 30 patients. These findings implicate that spliceosome mutations are rare in pediatric MDS and juvenile <b>myelomonocytic</b> <b>leukemia</b> and are unlikely to operate as driver mutations...|$|R
